Toxicity of artemisinin [Artemisia annua L.] in two different periods of pregnancy in Wistar rats

Reproductive Toxicology

Volumn 25, Issue 2, 2008, Pages 239-246

  Boareto, Ana C ^a   Muller, Juliane C ^a   Bufalo, Aedra C ^a   Botelho, Giuliana G K ^a   de Araujo, Samanta L ^a   Foglio, Mary Ann ^b   de Morais, Rosana N ^a   Dalsenter, Paulo R ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Antimalarial drug; Artemisinin; Embryolethality; Malaria; Pregnancy; Reproductive toxicity; Wistar rats

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ; GESTAGEN; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTEMISIA ANNUA; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEVELOPMENTAL STAGE; EMBRYO; FEMALE; GESTAGEN BLOOD LEVEL; GESTATION PERIOD; MALARIA; MALE; NIDATION; NONHUMAN; OUTCOME ASSESSMENT; PREGNANCY; PROGENY; RAT; REPRODUCTIVE TOXICITY; SENSITIVITY ANALYSIS; TESTOSTERONE BLOOD LEVEL;

ANIMALS; ANTIMALARIALS; ARTEMISIA ANNUA; ARTEMISININS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FETUS; MALE; PREGNANCY; PROGESTERONE; RATS; RATS, WISTAR; TESTOSTERONE;

ANIMALIA; ARTEMISIA ANNUA; RATTUS; RATTUS NORVEGICUS;

EID: 39749085830     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.reprotox.2007.11.003     Document Type: Article

References (39)

1. WHO-World Health Organization. Roll Back Malaria. Available in: http://www.rmb.who.int [cited January 5, 2006].
2. Ashley E., McGready R., Proux S., and Malaria N.F. Travel Med Infect Dis 4 3/4 (2006) 159-173
3. Olliaro P.L., and Taylor W.R.J. Antimalarial compounds: from bench to bedside. J Exp Biol 206 (2003) 3753-3759
4. Myint H.Y., Tipmanee P., and Nosten F. A systematic overview of published antimalarial drug trials. Trans R Soc Trop Med Hyg 98 (2004) 73-81
5. Whitty C.J.M., Allan R., Wiseman V., et al. Averting a malaria disarter in Africa-where does the buck stop?. Bull World Health Organization 82 5 (2004) 381-384
6. WHO-World Health Organization/UNICEF-United Nations Children's Fund. The Africa Malaria Report. Available in: http://www.afro.who/int.amd_2003/mainreport.pdf [cited January 13, 2006].
7. Noster F., Rogerson S.J., Beeson J.G., McGready R., Mutabingwa R.K., and Brabin B. Malaria in pregnancy and the endemicity spectrum: what can we learn?. Trend Parasitol 20 9 (2004) 425-432
8. Craig A.G. Pregnancy-associated malaria-on the brink?. Trends Parasitol 20 5 (2004) 2001-2004
9. Gordi T., and Lepist E.I. Artemisinin derivatives: toxic for laboratory animals, safe for humans?. Toxicol Lett 147 (2004) 99-107
10. Barnes K.I., and White N.J. Population biology and antimalarial resistance: the transmission of antimalarial drug resistance in Plasmodium falciparum. Acta Trop 94 (2005) 230-240
11. Dhingra V., Rao K.V., and Narasu M.L. Current status of artemisinina and its derivatives as antimalarial drugs. Life Sci 66 4 (2000) 279-300
12. Meshnick S.R. Artemisin: mechanisms of action, resistance and toxicity. Int J Parasitol 32 (2002) 1655-1660
13. McGready R., Cho T., Keo N.K., et al. Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum. Clin Infect Dis 33 (2001) 2009-2016
14. WHO-World Health Organization. Assessment of the safety of artemisinin compounds in pregnancy (2003), WHO, Geneva
15. Clark R.L., White T.E., Clodes A., Gaunt S.I., Winstanley P., and Ward S.A. Developmental toxicity of artesunate and an artesunate combination in the rat and rabbit. Birth Defects Res B Dev Reprod Toxicol 71 (2004) 380-394
16. Dellicour S., Hall S., Chandramohan D., and Greenwood B. The safety of artemsinins during pregnancy: a pressing question. Malaria J 6 (2007) 15
17. WHO-World Health Organization Regional Office for Africa. A strategic framework for malaria prevention and control during pregnancy in the African region (2004), WHO, Brazzaville
18. McGready R., Cho T., Cho J.J., et al. Artemisinin derivatives in the treatment of falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg 92 (1998) 430-433
19. McGready R., and Nostern F. The Thai-Burmese border: drug studies of Plasmodium falciparum in pregnancy. Ann Trop Med Parasitol 93 Suppl. 1 (1999) S2009-S2016
20. Longo M., Zanoncelli S., Della Torre P., et al. In vivo and in vitro investigations of the effects of the antimalarial drug dihydroartemisinin [DHA] on rat embryos. Reprod Toxicol 22 4 (2006) 797-810
21. White T.E.K., Bushidid P.B., Ritter S., Laffan S.B., and Clark R.L. Artesunate-induced depletion of embryonic erythroblasts precedes embryolethality and teratogenicity in vivo. Birth Defects Res [Part B] 77 (2006) 413-429
22. Rodrigues R.A.F., Foglio M.A., Boaventura Jr. S., Santos A.S., and Rehder V.L.G. Otimização do processo de extração e isolamento do antimalárico artemisinina a partir de Artemisia annua L. Quim Nova 19 2 (2006) 368-372
23. Woodrow C.J., Haynes R.K., Krishna S., and Artemisinins. Post Grad Med J 81 (2004) 71-78
24. Alin M.H., Ashton M., Kihamia C.M., Mtey G.J., and Bjorkman A. Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients. Trans R Soc Trop Med Hyg 90 (1990) 61-65
25. Hung L.N., Vries P.J., Thuy L.T.D., et al. Single dose artemisinin-mefloquine versus mefloquine alone uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 91 (1997) 191-194
26. Ashton M., Nguven D.S., Nguven V.H., et al. Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria. Clin Pharmacol Ther 63 4 (1998) 482-493
27. Agtmael M.A., Eggelte T.A., and van Boxtel C.J. Artemisinin drugs in the treatment of malaria: from medicinal herb to registered medication. Trends Pharmacol Sci 20 5 (1999) 199-205
28. Adjuik M., Babiker A., Garner P., Olliaro P., Taylor W., White N., and International Artemisinin Study Group. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 363 9402 (2004) 9-17
29. Munro C.J., Stabenfeldt G.H., Cragun J.R., Addiego L.A., Overstreet J.W., and Lasley B.L. The relationship of serum estradiol and progesterone concentrations to the excretion profiles of their major urinary metabolites as measured by enzyme-immunoassay and radioimmunoassay. Clin Chem 37 (1991) 838-844
30. Chahoud I., and Kwasigroch T.E. Controlled breeding of laboratory animal. In: Neubert D., Merker H.J., and Kwasigroch T.E. (Eds). Methods in prenatal toxicology evaluation of embryologic effects in experimental animals (1977), Teratology Workshop, Berlin 78-91
31. US EPA-US Environmental Protection Agency. Guidelines for reproductibe toxicity risk assessment. EPA/630/R-96/009. Washington; 1996.
32. US EPA-US Environmental Protection Agency. Endocrine disruptors screening program-Report to Congress. Washington; 2000.
33. Robb G.W., AMANN R.P., and Killian G.J. Daily sperm production and epididymal sperm reverses of pubertal and adult rats. J Reprod Fertil 54 (1978) 103-107
34. Ashby J., Lefevre P.A., Odum J., et al. Failure to confirm estrogenic activity for benzoic acid and clofibrate: implication for lists of endocrine-disrupting chemicals. Regul Toxicol Pharmacol 26 (1997) 96-101
35. Amann R.P. Use of animal models for detecting specific alterations in reproduction. Fundam Appl Pharmacol 2 82 (1982) 13-25
36. US EPA-US Environmental Protection Agency. Guidelines for developmental toxicity risk assessment. EPA/600/FR-91/001. Washington; 1991.
37. Longo M., Zanoncelli S., Manera D., et al. Effects of the antimalarial drug dihydroartemisinin [DHA] on rat embryo in vitro. Reprod Toxicol 21 1 (2006) 83-93
38. Orth J.M., Gunsalus G., and Lamperti A.A. Evidence from Sertoli cell-depleted rats indicates that spermatic number in adults depends on number of Sertoli cells produced during perinatal development. Endocrinology 122 (1988) 787-794
39. Nosten F., Vicenti M., Simpson J., et al. The effects of mefloquine treatment in pregnancy. Clin Inf Dis 28 (1999) 808